Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor vs Clopidogrel in NSTE-ACS Patients Undergoing PCI
NCT02052635Phase 4Terminated
- Sponsor
- AstraZeneca
- Start
- Sep 2014
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ticagrelor in non-ST elevation acute coronary syndrome (NSTE-ACS) (2 arms), sponsored by AstraZeneca. Primary endpoint: P2Y12 Reaction Units at 0.5 hours. Started Sep 2014; status: terminated.
02
Drugs
ticagrelor
03
Conditions
non-ST elevation acute coronary syndrome (NSTE-ACS)
Beyond the preview
Go deeper on NCT02052635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02052635.